Top Story

Baroreflex activation therapy may benefit HF patients without CRT

Baroreflex activation therapy may benefit HF patients without CRT
May 22, 2015

Read the Perspective from Michael R. Gold, MD, PhD, FHRS

BOSTON — For patients with HF who underwent baroreflex activation therapy, the magnitude of effect was greater in those without a chronic resynchronization therapy device, according to findings presented at the Heart Rhythm Society Annual Scientific Sessions.

The baroreflex activation therapy device (Barostim neo, CVRx Inc.) is a 2 mm electrode surgically implanted on the carotid sinus connected to a surgically implanted subcutaneous power unit. It works by stimulation of the carotid baroreceptor to reduce sympathetic activity and increase parasympathetic activity to stave off worsening symptoms and disease progression in patients with HF, according to the study background.

Meeting News Coverage

Atrial septal closure device explant may resolve nickel allergy symptoms

May 22, 2015
SAN DIEGO — Patients with nickel allergy and severe refractory symptoms after implantation with an atrial septal closure device experienced complete resolution of…

Evolocumab recommended for approval in Europe

May 22, 2015
Amgen announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the marketing authorization…
Arnold Greenspon, MD In the Journals

Repeat revisions for ICDs, CRT-Ds linked to substantial costs

May 22, 2015
When a patient with an implantable cardioverter defibrillator or a cardiac resynchronization therapy defibrillator undergoes more than one revision procedure…
Meeting News Coverage

High-intensity statin use low in patients with diabetes, high CVD risk

May 22, 2015
NASHVILLE, Tenn. - Patients with type 2 diabetes at very high risk for cardiovascular disease are often not taking high-intensity statins, further increasing their risk…
More News Headlines »
CME
Antiplatelet Therapy in ACS and PCI

Antiplatelet Therapy in ACS and PCI

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC.

It is estimated that in the United States, each year, over 780,000 persons will experience an acute coronary syndrome…
More »
Meeting News Coverage Video
VIDEO: Community awaits PCSK9 inhibitor phase 3 results, approval

VIDEO: Community awaits PCSK9 inhibitor phase 3 results, approval

May 17, 2015
SAN DIEGO — C. Noel Bairey Merz, MD, FACC, director of the Barbra Streisand Women’s Heart Center in the…
More »
CME
Examining Diverse Patient Populations and Their Response to Therapy

Examining Diverse Patient Populations and Their Response to Therapy

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC

Acute coronary syndrome (ACS) can result in substantial morbidity or death. To reduce the risk of cardiovascular death…
More »
morganatic-roan